Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
1. AQST prepares to present Anaphylm at the CFAAR Food Allergy Summit. 2. Anaphylm, if approved, will be the first oral epinephrine treatment in the U.S. 3. Studies show Anaphylm delivers rapid, consistent pharmacokinetic responses. 4. The product candidate is designed for real-world, extreme conditions. 5. FDA conditional approval emphasizes the importance of successful regulatory processes.